Medexus Pharmaceuticals Inc. (MDP.TO)
CAD 2.04
(-5.99%)
CAD 2.04
(-5.99%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 44.64 Million USD | -21.7% |
| 2022 | 57.01 Million USD | 27.14% |
| 2021 | 44.84 Million USD | 71.37% |
| 2020 | 26.16 Million USD | -22.06% |
| 2019 | 33.57 Million CAD | 771.11% |
| 2018 | -5 Million CAD | -953.35% |
| 2017 | 586.27 Thousand CAD | -27.79% |
| 2016 | 811.89 Thousand CAD | 202.28% |
| 2015 | -793.82 Thousand CAD | 68.66% |
| 2014 | -2.53 Million CAD | 64.23% |
| 2013 | -7.08 Million CAD | -1209.76% |
| 2012 | -540.6 Thousand CAD | -48.54% |
| 2011 | -363.94 Thousand CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 38.38 Million USD | -14.02% |
| 2023 Q4 | 44.64 Million USD | 1.28% |
| 2023 Q1 | 57.14 Million USD | 0.22% |
| 2023 Q2 | 52.58 Million USD | -7.97% |
| 2023 Q3 | 44.07 Million USD | -16.19% |
| 2023 FY | 44.64 Million USD | -21.7% |
| 2022 Q1 | 50.22 Million USD | 11.99% |
| 2022 Q4 | 57.01 Million USD | 1.11% |
| 2022 Q3 | 56.38 Million USD | 10.73% |
| 2022 FY | 57.01 Million USD | 27.14% |
| 2022 Q2 | 50.92 Million USD | 1.39% |
| 2021 Q2 | 39.25 Million USD | -5.43% |
| 2021 Q4 | 44.84 Million USD | 3.27% |
| 2021 Q3 | 43.42 Million USD | 10.63% |
| 2021 Q1 | 41.5 Million USD | 58.62% |
| 2021 FY | 44.84 Million USD | 71.37% |
| 2020 Q2 | 35.69 Million CAD | 10.02% |
| 2020 FY | 26.16 Million USD | -22.06% |
| 2020 Q3 | 41.21 Million CAD | 15.46% |
| 2020 Q4 | 26.16 Million USD | -36.51% |
| 2020 Q1 | 32.44 Million CAD | -3.36% |
| 2019 Q4 | 33.57 Million CAD | 1070.82% |
| 2019 FY | 33.57 Million CAD | 771.11% |
| 2019 Q3 | 2.86 Million CAD | 9390.69% |
| 2019 Q1 | -2.14 Million CAD | 57.11% |
| 2019 Q2 | 30.21 Thousand CAD | 101.41% |
| 2018 Q1 | 920.26 Thousand CAD | 56.97% |
| 2018 Q4 | -5 Million CAD | -3.84% |
| 2018 FY | -5 Million CAD | -953.35% |
| 2018 Q2 | 1.4 Million CAD | 52.87% |
| 2018 Q3 | -4.81 Million CAD | -442.49% |
| 2017 FY | 586.27 Thousand CAD | -27.79% |
| 2017 Q1 | -1.08 Million CAD | -233.39% |
| 2017 Q4 | 586.27 Thousand CAD | 988.21% |
| 2017 Q3 | 53.87 Thousand CAD | 116.61% |
| 2017 Q2 | -324.37 Thousand CAD | 70.05% |
| 2016 Q3 | 71.44 Thousand CAD | 109.35% |
| 2016 FY | 811.89 Thousand CAD | 202.28% |
| 2016 Q2 | -764.38 Thousand CAD | 60.35% |
| 2016 Q4 | 811.89 Thousand CAD | 1036.32% |
| 2016 Q1 | -1.92 Million CAD | -142.88% |
| 2015 Q2 | -330.72 Thousand CAD | 78.36% |
| 2015 Q1 | -1.52 Million CAD | 39.67% |
| 2015 FY | -793.82 Thousand CAD | 68.66% |
| 2015 Q4 | -793.82 Thousand CAD | -403.72% |
| 2015 Q3 | 261.37 Thousand CAD | 179.03% |
| 2014 Q3 | -2.34 Million CAD | 40.54% |
| 2014 Q2 | -3.93 Million CAD | 21.23% |
| 2014 FY | -2.53 Million CAD | 64.23% |
| 2014 Q1 | -4.99 Million CAD | 0.0% |
| 2014 Q4 | -2.53 Million CAD | -8.2% |
| 2013 Q1 | -483.62 Thousand CAD | 3.6% |
| 2013 Q2 | -459.82 Thousand CAD | 4.92% |
| 2013 Q3 | -5.18 Million CAD | -1028.56% |
| 2013 FY | -7.08 Million CAD | -1209.76% |
| 2012 Q1 | -535.57 Thousand CAD | 7.07% |
| 2012 Q2 | -551.07 Thousand CAD | -2.89% |
| 2012 FY | -540.6 Thousand CAD | -48.54% |
| 2012 Q4 | -501.67 Thousand CAD | -137.49% |
| 2012 Q3 | 1.33 Million CAD | 342.84% |
| 2011 FY | -363.94 Thousand CAD | 0.0% |
| 2011 Q3 | -363.94 Thousand CAD | 0.0% |
| 2011 Q4 | -576.31 Thousand CAD | -58.35% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Aurora Cannabis Inc. | -8.64 Million CAD | 616.2% |
| Avicanna Inc. | 1.32 Million CAD | -3266.086% |
| Avant Brands Inc. | 17.93 Million CAD | -148.974% |
| Cardiol Therapeutics Inc. | -34.77 Million CAD | 228.377% |
| Crescita Therapeutics Inc. | -8.13 Million CAD | 649.022% |
| Knight Therapeutics Inc. | 10.33 Million CAD | -332.149% |
| MediPharm Labs Corp. | -15.68 Million CAD | 384.591% |
| OrganiGram Holdings Inc. | -33.7 Million CAD | 232.431% |
| Canopy Growth Corporation | 512.87 Million CAD | 91.296% |
| Willow Biosciences Inc. | -989 Thousand CAD | 4613.751% |
| Auxly Cannabis Group Inc. | 142.88 Million CAD | 68.756% |